Unique Biological Properties of Catalytic Domain Directed Human Anti-CAIX Antibodies Discovered Through Phage-display Technology

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Mar 13

PMID 20224781

Citations 24

Authors

Chen Xu

Agnes Lo

Anuradha Yammanuru

Aimee St Clair Tallarico

Kristen Brady

Akikazu Murakami

Natasha Barteneva

Quan Zhu

Wayne A Marasco

Affiliations

Soon will be listed here.

Abstract

Carbonic anhydrase IX (CAIX, gene G250/MN-encoded transmembrane protein) is highly expressed in various human epithelial tumors such as renal clear cell carcinoma (RCC), but absent from the corresponding normal tissues. Besides the CA signal transduction activity, CAIX may serve as a biomarker in early stages of oncogenesis and also as a reliable marker of hypoxia, which is associated with tumor resistance to chemotherapy and radiotherapy. Although results from preclinical and clinical studies have shown CAIX as a promising target for detection and therapy for RCC, only a limited number of murine monoclonal antibodies (mAbs) and one humanized mAb are available for clinical testing and development. In this study, paramagnetic proteoliposomes of CAIX (CAIX-PMPLs) were constructed and used for anti-CAIX antibody selection from our 27 billion human single-chain antibody (scFv) phage display libraries. A panel of thirteen human scFvs that specifically recognize CAIX expressed on cell surface was identified, epitope mapped primarily to the CA domain, and affinity-binding constants (KD) determined. These human anti-CAIX mAbs are diverse in their functions including induction of surface CAIX internalization into endosomes and inhibition of the carbonic anhydrase activity, the latter being a unique feature that has not been previously reported for anti-CAIX antibodies. These human anti-CAIX antibodies are important reagents for development of new immunotherapies and diagnostic tools for RCC treatment as well as extending our knowledge on the basic structure-function relationships of the CAIX molecule.

Citing Articles

Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma.

OConnell R, Liaw K, Wellhausen N, Chuckran C, Bhojnagarwala P, Bordoloi D J Immunother Cancer. 2024; 12(6).

PMID: 38834201 PMC: 11163651. DOI: 10.1136/jitc-2023-008733.

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.

Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd C Mol Cancer. 2024; 23(1):56.

PMID: 38491381 PMC: 10943873. DOI: 10.1186/s12943-024-01952-w.

Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model.

Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A iScience. 2024; 27(2):108879.

PMID: 38327771 PMC: 10847687. DOI: 10.1016/j.isci.2024.108879.

Unique epitope-antibody interactions in the intrinsically disordered proteoglycan-like domain of human carbonic anhydrase IX defined by high-resolution NMR combined with yeast surface display.

Ni F, Wu C, Xu P, Wang P, Fortin Y, Arbour M MAbs. 2023; 15(1):2248672.

PMID: 37622732 PMC: 10461516. DOI: 10.1080/19420862.2023.2248672.

Quantitative Analysis of Latex Beads Phagocytosis by Human Macrophages Using Imaging Flow Cytometry with Extended Depth of Field (EDF).

Pavlova E, Shaposhnikova D, Petrichuk S, Radygina T, Erokhina M Methods Mol Biol. 2023; 2635:203-215.

PMID: 37074665 DOI: 10.1007/978-1-0716-3020-4_12.

References

Atkins M, Choueiri T, Cho D, Regan M, Signoretti S . Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009; 115(10 Suppl):2327-33. PMC: 2762357. DOI: 10.1002/cncr.24231. View

Divgi C, Pandit-Taskar N, Jungbluth A, Reuter V, Gonen M, Ruan S . Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007; 8(4):304-10. DOI: 10.1016/S1470-2045(07)70044-X. View

Motzer R, Russo P . Systemic therapy for renal cell carcinoma. J Urol. 2000; 163(2):408-17. View

Parkkila S, Rajaniemi H, Parkkila A, Kivela J, Waheed A, Pastorekova S . Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A. 2000; 97(5):2220-4. PMC: 15781. DOI: 10.1073/pnas.040554897. View

Grabmaier K, Vissers J, De Weijert M, Oosterwijk-Wakka J, van Bokhoven A, Brakenhoff R . Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000; 85(6):865-70. DOI: 10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q. View

Motzer R, Mazumdar M, Bacik J, Russo P, Berg W, Metz E . Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18(9):1928-35. DOI: 10.1200/JCO.2000.18.9.1928. View

Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J . Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000; 82(11):1808-13. PMC: 2363230. DOI: 10.1054/bjoc.2000.1111. View

Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J . Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol. 2000; 18(6):649-54. DOI: 10.1038/76501. View

Beavon I . The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer. 2000; 36(13 Spec No):1607-20. DOI: 10.1016/s0959-8049(00)00158-1. View

10.

Ivanov S, Liao S, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G . Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001; 158(3):905-19. PMC: 1850340. DOI: 10.1016/S0002-9440(10)64038-2. View

11.

Maher J, Brentjens R, Gunset G, Riviere I, Sadelain M . Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2001; 20(1):70-5. DOI: 10.1038/nbt0102-70. View

12.

Bui M, Seligson D, Han K, Pantuck A, Dorey F, Huang Y . Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9(2):802-11. View

13.

Michael A, Pandha H . Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol. 2003; 4(4):215-23. DOI: 10.1016/s1470-2045(03)01044-1. View

14.

Pinthus J, Waks T, Kaufman-Francis K, Schindler D, Harmelin A, Kanety H . Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 2003; 63(10):2470-6. View

15.

Bleumer I, Oosterwijk E, De Mulder P, Mulders P . Immunotherapy for renal cell carcinoma. Eur Urol. 2003; 44(1):65-75. DOI: 10.1016/s0302-2838(03)00191-x. View

16.

Guindon S, Gascuel O . A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003; 52(5):696-704. DOI: 10.1080/10635150390235520. View

17.

Svastova E, Zilka N, Zatovicova M, Gibadulinova A, ciampor F, Pastorek J . Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 2003; 290(2):332-45. DOI: 10.1016/s0014-4827(03)00351-3. View

18.

Zatovicova M, Tarabkova K, Svastova E, Gibadulinova A, Mucha V, Jakubickova L . Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 2003; 282(1-2):117-34. DOI: 10.1016/j.jim.2003.08.011. View

19.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C . A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004; 90(5):985-90. PMC: 2410216. DOI: 10.1038/sj.bjc.6601617. View

20.

Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S . Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics. 2004; 4(6):1633-49. DOI: 10.1002/pmic.200300771. View